Novo Nordisk, A Leading Global Healthcare Company, Announced That The Us Food And Drug Administration (Fda) Has Approved A 2.0 Mg Dose Of Ozempic (Once-Weekly Semaglutide Subcutaneous Injection), A Glucagon-Like Peptide-1 (Glp-1) Analogue For The Treatment Of Adults With Type 2 Diabetes. Ozempic Is Now Approved In The Us At 0.5 Mg,1.0 Mg And 2.0 Mg Doses For The Treatment Of Type 2 Diabetes In Adults. Further, Ozempic Is Indicated To Reduce The Risk Of Major Cardiovascular Events Such As Heart Attack, Stroke Or Death In Adults With Type 2 Diabetes And Known Heart Disease.The Fda Approval Is Based On The Results From The Sustain Forte Trial. In The Trial, People Treated With Semaglutide 2.0 Mg Achieved A Statistically Significant And Superior Reduction In Hba1C At Week 40 Compared To Semaglutide 1.0 Mg. In The Trial, Both Doses Of Semaglutide Appeared To Have A Safe And Well-Tolerated Profile. The Most Common Adverse Events Were Gastrointestinal. Compared To Semaglutide 1.0 Mg, The Gastrointestinal Adverse Events Were Similar For Semaglutide 2.0 Mg.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!